Hennion & Walsh Asset Management, Inc.
Position in ORGO — Organogenesis Holdings Inc.
CIK 1861642
Parsippany, NJ
Position in ORGO
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$507,862
+$8,205 QoQ
Shares Held
208,997
-0.9% QoQ
Ownership
0.162%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#33
of 135 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ORGO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Hennion & Walsh Asset Management, Inc. holds $46,273,526 across 11 Drug Manufacturers - Specialty & Generic names. ORGO ranks #11 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INDV |
Indivior Pharmaceuticals, Inc.
|
360,245 | $14,780,852 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
|
327,801 | $11,105,897 | |
| 3 | PCRX |
Pacira BioSciences, Inc.
|
203,520 | $5,163,302 | |
| 4 | SUPN |
Supernus Pharmaceuticals, Inc.
|
90,213 | $4,195,806 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
6,097 | $3,303,537 | |
| 6 | ALKS |
Alkermes plc.
|
47,317 | $2,479,174 | |
| 7 | VTRS |
Viatris Inc
|
104,642 | $1,661,714 | |
| 8 | BCRX |
Biocryst Pharmaceuticals Inc
|
112,893 | $1,128,930 |
All Filings in ORGO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $507,862 | 208,997 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $499,657 | 210,826 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $1,079,206 | 208,341 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $669,882 | 158,740 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $341,869 | 93,407 | Shares | Sole | 2025-08-07 | |
| No filing history on record for this holder in this stock. | ||||||